Acquisitions & PartnershipsBioprinting

CollPlant and 3D Systems developing tissue and scaffold bioprinting solutions

AM giant 3D Systems has announced a joint development partnership with biotech company CollPlant, a developer of proprietary bioink products (rhCollagen) for 3D bioprinting tissues. Working together, the companies will leverage 3D Systems expertise in 3D printing and healthcare applications and CollPlant’s deep knowledge of bioinks to jointly develop tissue and scaffold bioprinting processes for third party collaborators.

The partnership’s overall goal is to develop bioprinting technologies in order to advance regenerative medicine research. The companies are determined to create an integrated bioprinting solution (or solutions) targeted specifically at printing tissues and scaffolds for regenerative medicine applications.

CollPlant 3D Systems bioprinting partnership

Through the collaboration, 3D Systems and CollPlant will both have access to the former’s 3D printers and the latter’s BioInks, as well as new formulations of rhCollagen-based inks developed jointly by the companies. The combination of printing technology and materials can be leveraged for their own products as well as by third parties.

“3D Systems is excited to work with CollPlant to develop groundbreaking bioprinted tissue and scaffold technologies,” commented Chuck Hull, Co-Founder and CTO of 3D Systems. “We believe 3D printing to be a key technology for regenerative medicine, and this collaboration is one of many we are entering to play an integral role in this exciting field. Combining our innovative 3D printing technologies with CollPlant’s rhCollagen-based BioInks has the potential to make a significant impact in bioprinting and regenerative medicine.”

Yehiel Tal, CEO of CollPlant, added: ”We strongly believe that our proven rhCollagen is the finest building block for regenerative medicine tissues and scaffolds available today. As the leading additive manufacturing printing solutions company, 3D Systems is the perfect partner for us. Together, we can offer the best combined technology for 3D bioprinting. We are honored to have established this important collaboration and we look forward to working together to advance 3D bioprinting technology to the commercial phase.”

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Back to top button

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!